However, despite encouraging survival results and immunological data, clinical trials have defined several problems impairing the clinical utility of IFN-α for pancreatic cancer patients: (i) Systemic toxicity of IFN-α, and (ii) Insufficient delivery and unsustainable levels of IFN-α in the tumor site due to rapid degradation of the cytokine in blood circulation and low vascularity [71,72]. The gene discussed is IFNA1; the disease is neoplasm.